Options Data for US Stocks: End-of-Day and Historical Learn more

aTyr Pharma, Inc. icon

aTyr Pharma, Inc. (ATYR NASDAQ) stock market data APIs

$6.1133 0.1(1.6%)
as of November 13, 2026
Try our APIs with free plan!

aTyr Pharma, Inc. Financial Data Overview

Price chart is built with Anychart

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company has a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Prev. Close 6.1133
Open 6.209
High 6.4773
Low 5.989
52 wk Range 4.068-44.4
Market Cap 15 563 K
Shares Outstanding 2 549 K
EPS -7.43
Beta 1.048

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get aTyr Pharma, Inc. data using free add-ons & libraries


Get aTyr Pharma, Inc. Fundamental Data

aTyr Pharma, Inc. logo

aTyr Pharma, Inc. Fundamental data includes:

  • Net Revenue:
  • EBITDA: -55 238 000
  • Earnings Per Share: -21
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get aTyr Pharma, Inc. Earnings data

Corporate Events Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2026-11-05
  • EPS/Forecast: -4.4
GET THE PACKAGE

Get aTyr Pharma, Inc. End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

aTyr Pharma, Inc. News

Get aTyr Pharma, Inc. fresh news feed via Financial News API

Corporate Events Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE

Send the request

Leave your email and our team will contact you ASAP.